UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063710
Receipt number R000072900
Scientific Title A Multicenter, Open-Label, Randomized Controlled Trial of Recombinant Thrombomodulin Monotherapy versus Antithrombin and Recombinant Thrombomodulin Combination Therapy for Sepsis-Induced Disseminated Intravascular Coagulation
Date of disclosure of the study information 2026/11/20
Last modified on 2026/11/20 16:02:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized Controlled Trial of rTM Monotherapy vs. AT+rTM Combination Therapy for Sepsis-Induced DIC

Acronym

The STARLET (Sepsis Therapy with Antithrombin and Recombinant LE Thrombomodulin) trial

Scientific Title

A Multicenter, Open-Label, Randomized Controlled Trial of Recombinant Thrombomodulin Monotherapy versus Antithrombin and Recombinant Thrombomodulin Combination Therapy for Sepsis-Induced Disseminated Intravascular Coagulation

Scientific Title:Acronym

The STARLET (Sepsis Therapy with Antithrombin and Recombinant LE Thrombomodulin) trial

Region

Japan


Condition

Condition

Sepsis-induced disseminated intravascular coagulation (Sepsis-induced DIC)

Classification by specialty

Anesthesiology Emergency medicine Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To scientifically evaluate the efficacy (improvement in DIC resolution rate on Day 3, etc.) and safety (hemorrhagic adverse events, etc.) of combination therapy with recombinant thrombomodulin (rTM) and antithrombin (AT) compared with rTM monotherapy in adult patients with sepsis-induced DIC and AT activity <= 70% in a multicenter randomized controlled trial.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

DIC resolution rate on Day 3 after treatment initiation

Key secondary outcomes

28-day and 90-day mortality
Improvement in organ dysfunction (change in SOFA score)
ICU-free days Hemorrhagic adverse events (classified according to ISTH bleeding criteria)
Changes in biomarkers (DAMPs: Histone, HMGB-1, syndecan-1, cf-DNA, etc.; at participating DAMPs-measurement sites only)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

In addition to standard therapy, intravenous administration of recombinant thrombomodulin (rTM) at 380 U/kg (0.06 mg/kg)/day (once daily over 30 minutes, without dose reduction for renal dysfunction) for 6 days and antithrombin (AT) at 50 IU/kg/day for 5 days.

Interventions/Control_2

In addition to standard therapy, intravenous administration of recombinant thrombomodulin (rTM) at 380 U/kg (0.06 mg/kg)/day (once daily over 30 minutes, without dose reduction for renal dysfunction) for 6 days.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Aged 18 years or older at enrollment.
Diagnosed with sepsis meeting the Sepsis-3 definition.
Acute DIC diagnostic criteria (JAAM2-DIC score) >= 3.
Antithrombin (AT) activity <= 70%.
Written informed consent obtained from the patient or legally authorized representative.

Key exclusion criteria

Underlying hematological malignancy such as leukemia or myelodysplastic syndrome.
Expected survival of less than 24 hours at the time of enrollment as judged by the attending physician.
Severe hepatic dysfunction (e.g., Child-Pugh class C).
Active bleeding or extremely high risk of bleeding.
Pregnant or breastfeeding.

Target sample size

70


Research contact person

Name of lead principal investigator

1st name Takaaki
Middle name
Last name Totoki

Organization

Osaka Medical and Pharmaceutical University

Division name

Department of Anesthesiology

Zip code

5698686

Address

2-7 Daigakumachi, Takatsuki, Osaka

TEL

84035329

Email

ttktkak@gmail.com


Public contact

Name of contact person

1st name TAKAAKI
Middle name
Last name TOTOKI

Organization

Osaka Medical and Pharmaceutical University

Division name

Department of Anesthesiology

Zip code

5690804

Address

2-7 Daigakumachi, Takatsuki, Osaka

TEL

84035329

Homepage URL


Email

takaaki.totoki@ompu.ac.jp


Sponsor or person

Institute

Osaka Medical and Pharmaceutical University

Institute

Department

Personal name



Funding Source

Organization

Osaka Medical and Pharmaceutical University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka Medical and Pharmaceutical University

Address

2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan

Tel

072-683-1221

Email

takaaki.totoki@ompu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 11 Month 20 Day

Date of IRB


Anticipated trial start date

2026 Year 12 Month 01 Day

Last follow-up date

2028 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 11 Month 20 Day

Last modified on

2026 Year 11 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072900